Estimating the cost of new drug development: is it really 802 million dollars?

Health Affairs
Christopher P Adams, Van V Brantner

Abstract

This paper replicates the drug development cost estimates of Joseph DiMasi and colleagues ("The Price of Innovation"), using their published cost estimates along with information on success rates and durations from a publicly available data set. For drugs entering human clinical trials for the first time between 1989 and 2002, the paper estimated the cost per new drug to be 868 million dollars. However, our estimates vary from around 500 million dollars to more than 2,000 million dollars, depending on the therapy or the developing firm.

References

Jan 2, 1997·The Rand Journal of Economics·R Henderson, I Cockburn
Feb 28, 2003·Journal of Health Economics·Joseph A DiMasiHenry G Grabowski
Jul 30, 2005·Nature Reviews. Drug Discovery·Ernst R BerndtMatthew W Strobeck

❮ Previous
Next ❯

Citations

Oct 7, 2010·Analytical and Bioanalytical Chemistry·Megan A HahnBrij M Moudgil
Dec 25, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·J LundqvistB Jönsson
Nov 12, 2009·Cell Biology and Toxicology·Sally L Hampton, Anne I Kinnaird
Aug 25, 2012·Digestive Diseases and Sciences·Alan R ZinsmeisterMichael Camilleri
Jan 18, 2012·Targeted Oncology·Paul Cornes
Sep 20, 2012·International Journal of Technology Assessment in Health Care·Nguyen Xuan ThanhPhilip Jacobs
May 17, 2011·Journal of Chemical Information and Modeling·Jintao ZhangJun Huan
Jan 3, 2013·Journal of Chemical Information and Modeling·Chao MaXiang-Qun Xie
Feb 26, 2010·Journal of Medicinal Chemistry·Amanda J DeGrawMark D Distefano
Apr 7, 2011·The Journal of Antibiotics·Rahul Kunwar SinghTribhuban M Mohapatra
Oct 2, 2012·Nature Biotechnology·Jose-Maria FernandezAndrew W Lo
Nov 9, 2007·Nature Biotechnology·Daniel Ricklin, John D Lambris
Jun 19, 2009·Nature Chemical Biology·Tudor I OpreaLarry A Sklar
Feb 2, 2011·Nature Reviews. Clinical Oncology·Edina Komlodi-PasztorTito Fojo
Oct 2, 2013·Nature Reviews. Clinical Oncology·Lajos PusztaiFabrice Andre
Oct 3, 2007·Nature Reviews. Drug Discovery·Lisette OversteegenMark J Belsey
May 13, 2008·Nature Reviews. Drug Discovery·Henry Grabowski
Jun 2, 2011·Nature Reviews. Drug Discovery·Fabio PammolliMassimo Riccaboni
Dec 10, 2009·The American Journal of Bioethics : AJOB·Fritz Allhoff
Oct 2, 2007·Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science·Gigi Kwik GronvallTara O'Toole
Dec 27, 2007·Cancer Biotherapy & Radiopharmaceuticals·Adrian D Nunn
Oct 10, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B SerugaI F Tannock
Jun 22, 2011·Briefings in Bioinformatics·Joel T DudleyAtul J Butte
Oct 19, 2012·The Journal of Antimicrobial Chemotherapy·Juan Carlos Palomino, Anandi Martin
Jun 29, 2011·Journal of the National Cancer Institute·Manish R SharmaMark J Ratain
Nov 13, 2010·Nucleic Acids Research·Joachim von EichbornRobert Preissner
Dec 18, 2007·Genome Research·Lixia Yao, Andrey Rzhetsky
Jun 13, 2009·Science·Mark S BoguskiVikas P Sukhatme
Jul 1, 2010·Molekuliarnaia biologiia·A E IvlievM G Sergeeva
Jul 28, 2009·Annual Review of Genomics and Human Genetics·Kevin A Strauss, Erik G Puffenberger
Jan 12, 2008·Annual Review of Medicine·Janet Woodcock, Raymond Woosley
Apr 5, 2011·Computational and Mathematical Methods in Medicine·Jana L Gevertz
Jun 4, 2013·American Journal of Respiratory and Critical Care Medicine·John Concato
Oct 26, 2011·BMC Bioinformatics·Jintao ZhangJun Huan
Jul 12, 2011·Philosophy, Ethics, and Humanities in Medicine : PEHM·Fenella CorrickSanjay Budhdeo
Jul 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Terre A McJoyntS Vincent Rajkumar
May 21, 2011·The Journal of Economic Perspectives : a Journal of the American Economic Association·Amitabh ChandraJonathan S Skinner
Aug 27, 2009·PLoS Neglected Tropical Diseases·Solomon NwakaRobert Ridley
Sep 14, 2012·Drug Metabolism and Pharmacokinetics·Naoe YamaneYuichi Sugiyama
Jul 26, 2011·AJR. American Journal of Roentgenology·Daniel Y Lee, King C P Li
Dec 17, 2009·Future Oncology·Michael C Kolios, Gregory J Czarnota
Dec 14, 2011·Future Oncology·Nalân Utku

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Health Economics
Christopher P Adams, Van V Brantner
Journal of Health Economics
Joseph A DiMasiH G Grabowski
Nature Reviews. Drug Discovery
Ismail Kola, John Landis
Journal of Health Economics
Joseph A DiMasiL Lasagna
© 2021 Meta ULC. All rights reserved